Skip to main content
SpringerLink
Log in

Marimastat

BB 2516, TA 2516

  • Section 1: Matrix Metalloprotease Inhibitor
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Millar AW, Brown PD, Moore J, et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol 1998 Jan; 45: 21–6

    Article  PubMed  CAS  Google Scholar 

  2. Rusmussen H, Rugg T, Brown P, et al. A 371 patient meta-analysis of studies of marimastat in patients with advanced cancer. 33rd Annual Meeting of the American Society of Clinical Oncology 1997 May 17–20; Denver. Proc Am Soc Clin Oncol 1997; 429

    Google Scholar 

  3. Evans J, Bramhall S, Carmichael J, et al. A phase II study of marimastat (BB-2516) in advanced pancreatic cancer. Ann Oncol 1996; 7 Suppl. 5: 51

    Google Scholar 

  4. Boasberg P, Harbaugh, Eisenberger M, et al. Marimastat in patients with hormone refractory prostate cancer: a dose-finding study. 33rd Annual Meeting of the American Society of Clinical Oncology 1997 May 17–20; Denver. Proc Am Soc Clin Oncol 1997; 316

    Google Scholar 

  5. Bodurtha A, Eisenhauer E, Steward W, et al. Phase I-II study of marimastat (BB2516) in patients with metastatic melanoma. 33rd Annual Meeting of the American Society of Clinical Oncology 1997 May 17–20; Denver. Proc Am Soc Clin Oncol 1997; 493

    Google Scholar 

  6. Wojtowicz-Praga S, Torri J, Johnson M, et al. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998 Jun; 16: 2150–6

    PubMed  CAS  Google Scholar 

  7. Parson SL, Watson SA, Griffin NR, et al. A phase I/II study of the oral matrix metalloproteinase inhibitor, marimastat, in patients with inoperable gastric cancer. Gastroenterology 1997 Apr; 112 Suppl.: 636

    Google Scholar 

  8. Malfetano J, Teng N, Barter J, et al. Marimastat in patients with advanced cancer of the ovary — a dose-finding study. 33rd Annual Meeting of the American Society of Clinical Oncology. 1997 May 17–20; Denver. Proc Am Soc Clin Oncol 1997; 373

    Google Scholar 

  9. White JD, Carmichael J, Woll PJ, et al. Phase 1B study of concurrent administration of marimastat and gemcitabine in nonresectable pancreatic cancer. Br J Cancer 1998; 78 Suppl. 2: 30

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marimastat. Drugs R&D 1, 146–149 (1999). https://doi.org/10.2165/00126839-199901020-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199901020-00008

Keywords

Search

Navigation